Sofosbuvir for Hepatitis C Genotype 2 or 3 in Patients without Treatment Options

M. Jacobson, Ira; C. Gordon, Stuart; V. Kowdley, Kris; M. Yoshida, Eric; Rodríguez‐Torres, M.; Sulkowski, Mark; L. Shiffman, Mitchell; Lawitz, Eric; T. Everson, Gregory; Bennett, Michael; R. Schiff, Eugene; Tarek Al-Assi, M.; Mani Subramanian, G.; An, Di; Lin, M.; McNally, John; M. Brainard, Diana; T. Symonds, William; G. McHutchison, John; Patel, Keyur; J. Feld, Jordan; Pianko, Stephen; R. Nelson, David

doi:10.1056/nejmoa1214854

Public

Sofosbuvir for Hepatitis C Genotype 2 or 3 in Patients without Treatment Options

Published in New England Journal of Medicine • Apr 23, 2013

Authors:

Ira M. Jacobson

Stuart C. Gordon

Kris V. Kowdley

Abstract

BACKGROUND: Patients chronically infected with hepatitis C virus (HCV) genotype 2 or 3 for whom treatment with peginterferon is not an option, or who have not had a response to prior interferon treatment, currently have no approved treatment options. In phase 2 trials, regimens including the oral nu...

Subject

Medicine

Sofosbuvir

Ribavirin

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!